315 related articles for article (PubMed ID: 22271656)
1. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
2. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
3. An Outcome-Based Approach to Assign MELD Exception Points for Patients With Hepatocellular Cancer.
Kensinger CD; Feurer ID; Karp SJ
Transplantation; 2017 Sep; 101(9):2056-2061. PubMed ID: 28471871
[TBL] [Abstract][Full Text] [Related]
4. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.
Ishaque T; Massie AB; Bowring MG; Haugen CE; Ruck JM; Halpern SE; Waldram MM; Henderson ML; Garonzik Wang JM; Cameron AM; Philosophe B; Ottmann S; Rositch AF; Segev DL
Am J Transplant; 2019 Feb; 19(2):564-572. PubMed ID: 30312530
[TBL] [Abstract][Full Text] [Related]
5. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
6. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
[TBL] [Abstract][Full Text] [Related]
7. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
Alver SK; Lorenz DJ; Marvin MR; Brock GN
Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
9. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
10. Center variation in the use of nonstandardized model for end-stage liver disease exception points.
Goldberg DS; Makar G; Bittermann T; French B
Liver Transpl; 2013 Dec; 19(12):1330-42. PubMed ID: 24039090
[TBL] [Abstract][Full Text] [Related]
11. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
[TBL] [Abstract][Full Text] [Related]
12. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
[TBL] [Abstract][Full Text] [Related]
13. Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approach.
Bittermann T; Niu B; Hoteit MA; Goldberg D
Am J Transplant; 2014 Jan; 14(1):79-87. PubMed ID: 24304509
[TBL] [Abstract][Full Text] [Related]
14. HCC patients suffer less from geographic differences in organ availability.
Schuetz C; Dong N; Smoot E; Elias N; Schoenfeld DA; Markmann JF; Yeh H
Am J Transplant; 2013 Nov; 13(11):2989-95. PubMed ID: 24011291
[TBL] [Abstract][Full Text] [Related]
15. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
[TBL] [Abstract][Full Text] [Related]
16. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
[TBL] [Abstract][Full Text] [Related]
17. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.
Nobel YR; Goldberg DS
Transplantation; 2015 Nov; 99(11):2341-6. PubMed ID: 25989503
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatocellular carcinoma: the MELD impact.
Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.
Alver SK; Lorenz DJ; Washburn K; Marvin MR; Brock GN
Transpl Int; 2017 Nov; 30(11):1098-1109. PubMed ID: 28403575
[TBL] [Abstract][Full Text] [Related]
20. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
